Home > Insider Trading > Filing (0001104659-24-091346)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1326190	Altimmune Inc.	ALT	Pharmaceutical Preparations (2834)	202726770

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1428764	David Drutz	C/O Altimmune, Inc., 910 Clopper Road, Suite 201S Gaithersburg MD 20878		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001	Acquisiton	2024-08-19	20,000	$2.60	49,785	No	4	M	Indirect	See Footnote
Common Stock, Par Value $0.0001	Disposition	2024-08-19	7,827	$6.93	41,958	No	4	S	Indirect	See Footnote
Common Stock, Par Value $0.0001	Acquisiton	2024-08-19	21,750	$2.50	63,708	No	4	M	Indirect	See Footnote
Common Stock, Par Value $0.0001	Disposition	2024-08-19	8,184	$6.88	55,524	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	M	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, Par Value $0.0001	Stock Options (option to buy)	Disposition	2024-08-19	20,000	$0.00	20,000	$2.60
Common Stock, Par Value $0.0001	Stock Options (option to buy)	Disposition	2024-08-19	21,750	$0.00	21,750	$2.50

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2029-01-02	No	4	M	Direct
4,350		2033-09-28	No	4	M	Direct

Footnotes

Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC.
Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.
This sale represents shares sold to cover the exercise price.
The shares underlying the option became vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date.
The shares underlying the option became vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date.